5443-88-9

Usage

Uses

Used in Pharmaceutical Applications:
6-Allylthiopurine is used as a pharmaceutical candidate for its reported antitumor and antioxidant properties. It is being studied for its potential to inhibit the enzyme xanthine oxidase, which is involved in the production of reactive oxygen species, thereby contributing to the development of treatments for various diseases and conditions.
Used in Enzyme Inhibition:
In the field of enzyme research, 6-allylthiopurine is used as an inhibitor of the enzyme xanthine oxidase. This application is significant for managing conditions related to the overproduction of reactive oxygen species, which can lead to oxidative stress and associated health issues.

InChI:InChI=1/C8H8N4S/c1-2-3-13-8-6-7(10-4-9-6)11-5-12-8/h2,4-6H,1,3H2

Upstream product

• 157930-09-1 6-Mercaptopurine 
• 107-05-1 3-chloroprop-1-ene 
• 106-95-6 allyl bromide 

Downstream Products

• 1374683-12-1 7-[(4-nitrophenylsulfanyl)methyl]-7,8-dihydro-[1,3]thiazolo[2,3-i]purine 
• 1424011-92-6 7-[(4-nitrophenylsulfanyl)methyl]-7,8-dihydro-[1,3]thiazolo[2,3-i]purin-6-ium perchlorate 
• 1374684-98-6 7-[(4-methylphenylsulfanyl)methyl]-7,8-dihydro-[1,3]thiazolo[2,3-i]purine 
• 1424011-89-1 7-[(4-methylphenylsulfanyl)methyl]-7,8-dihydro-[1,3]thiazolo[2,3-i]purin-6-ium perchlorate 
• 1424011-86-8 7-[(phenylsulfanyl)methyl]-7,8-dihydro[1,3]-thiazolo[2,3-i]purin-6-ium perchlorate 

Relevant academic research and scientific papers

Synthesis of derivatives of 7,8-dihydrothiazolo[2,3-i]purine by halocyclization of 6-allylthiopurine

7-Halomethyl-7,8-dihydrothiazolo[2,3-i]purines were synthesized by the reaction of bromine and iodine with 6-allylthiopurine.

9-Sulfonyl-9(H)-Purine Derivatives Inhibit HCV Replication Via their Degradation Species

Cell-based screening of a privileged small molecule library led to the discovery of 9-sulfonyl-9(H)-purine as new scaffold for hepatitis C virus (HCV) inhibitors. Structure–activity relationship study with respect to the 2-, 6- and 9-positions in the purine core resulted in the identification of several active compounds with moderate potency against the HCV genotype 1b. Subsequent stability studies demonstrated that HCV inhibitors of this type were unstable in Dulbecco’s modified eagle medium (DMEM) and plasma, as well as glutathione-containing water, and their instability was closely related to their HCV inhibitory activity. A preliminary study of the mechanism of action showed that the sulfonamide bond at the 9-position of purine would be the primary degradation site and the resulting sulfonylation degradation species would mediate the anti-HCV activity of 9-sulfonyl-9(H)-purines. Results of this study demonstrated that 9-sulfonyl-9(H)-purine is an unstable scaffold for HCV inhibitors and further detailed analysis of the degradation species is needed to determine the main active components and direct target for this type of molecules.